Jaguar Health (FRA:1JA1) Beta: -0.2187 (As of Jun. 26, 2026)


FRA:1JA1 Jaguar Health Inc FRA:1JA1
22 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is Jaguar Health Beta?

Jaguar Health FRA:1JA1 22 Beta is -0.2187 as of Jun. 26, 2026. GuruFocus rates FRA:1JA1 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Jaguar Health's Beta is -0.2187.


Jaguar Health  (FRA:1JA1) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Jaguar Health Beta Related Terms


Jaguar Health Beta Historical Data

* Premium members only.

The historical data trend for Jaguar Health's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health Beta Chart

Jaguar Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 1.52 0.20 1.21 2.31

Jaguar Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.86 0.51 2.31 0.24

FRA:1JA1 vs BBLG, VBIO, PKTX: Beta Comparison

For the Biotechnology subindustry, Jaguar Health's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Beta distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Beta falls into.


FRA:1JA1
22GF Score
Jaguar Health Inc FRA:1JA1
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jaguar Health Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2187 mean?
Jaguar Health (FRA:1JA1) has a Beta of -0.2187 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jaguar Health and its competitors.
Is Jaguar Health's Beta too high?
Jaguar Health's current Beta is -0.2187. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Beta compare to BBLG and VBIO?
Jaguar Health's Beta of -0.2187 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jaguar Health and its competitors. Jaguar Health's current Beta is -0.2187. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (FRA:1JA1) has a current Beta of -0.2187. The current Beta is -0.2187. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Jaguar Health (FRA:1JA1), the current Beta is -0.2187 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jaguar Health Business Description

Other Exchanges JAGX:USA
Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score

Get the complete analysis for FRA:1JA1

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price